CBD has low CB1 affinity but modulates multiple targets (5-HT1A, TRPV, PPAR-γ), showing evidence for epilepsy and potential for anxiety, inflammation, and pain modulation. It can affect CYP450 metabolism—knowledge that matters for safety.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
